Cargando…
The prevalence, comorbidities, influencing factors, and identifying factors of non-obese fatty liver disease
OBJECTIVE: To analyze the prevalence, associated comorbidities, influencing factors, and identifying factors of non-obese fatty liver disease and to provide a reference for its prevention and treatment. MATERIALS AND METHODS: Firstly, to screen data obtained from the physical examinations of individ...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705575/ https://www.ncbi.nlm.nih.gov/pubmed/36457563 http://dx.doi.org/10.3389/fmed.2022.1038475 |
_version_ | 1784840314865844224 |
---|---|
author | Gao, Ning Deng, Jiang Wang, Jinhai Zhou, Zhihua Yao, Cong Zhou, Mimi Xing, Xin Wang, Qian Lu, Xiaolan Shi, Haitao |
author_facet | Gao, Ning Deng, Jiang Wang, Jinhai Zhou, Zhihua Yao, Cong Zhou, Mimi Xing, Xin Wang, Qian Lu, Xiaolan Shi, Haitao |
author_sort | Gao, Ning |
collection | PubMed |
description | OBJECTIVE: To analyze the prevalence, associated comorbidities, influencing factors, and identifying factors of non-obese fatty liver disease and to provide a reference for its prevention and treatment. MATERIALS AND METHODS: Firstly, to screen data obtained from the physical examinations of individuals conducted in the Second Affiliated Hospital of Xi’an Jiaotong University in 2021, subjects with complete data of abdominal ultrasonography, body mass index, age and sex were selected to analyze the prevalence of fatty liver disease and non-obese fatty liver disease. Secondly, to screen non-obese subjects who had data for triglycerides, fasting blood glucose, and so on, to analyze the complications, influencing factors, and identifying factors of non-obese fatty liver disease. RESULTS: The prevalence of fatty liver disease was 27.8% (18,416/66,221), including 33.9% (11,921/35,131) in males and 20.9% (6,495/31,090) in females, revealing that the prevalence was significantly higher in males than in females (P < 0.001). There were 40,673 non-obese subjects screened in total, and the prevalence of non-obese fatty liver disease was 13.0% (5,307/40,673). The prevalence of non-obese fatty liver disease was 13.3% (2,208/16,572) in males and 12.9% (3,099/24,101) in females; the difference was not statistically significant (P = 0.17). The serum triglycerides level was elevated in 54.2% of subjects with non-obese fatty liver disease, and this was the most common abnormal metabolic index accompanying the disease. Logistic regression analysis showed that gender, age, body mass index, blood pressure, alanine aminotransferase, aspartate aminotransferase, fasting blood glucose, triglycerides, total cholesterol, and serum uric acid were independent risk factors for non-obese fatty liver disease (P < 0.001). For triglycerides, the area under the receiver operating characteristic curve in predicting non-obese fatty liver disease was the greatest (0.806). CONCLUSION: The prevalence of fatty liver disease and non-obese fatty liver disease determined by the physical examination of individuals was high, and the triglycerides is likely to be useful for the extensive screening of non-obese fatty liver disease. |
format | Online Article Text |
id | pubmed-9705575 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97055752022-11-30 The prevalence, comorbidities, influencing factors, and identifying factors of non-obese fatty liver disease Gao, Ning Deng, Jiang Wang, Jinhai Zhou, Zhihua Yao, Cong Zhou, Mimi Xing, Xin Wang, Qian Lu, Xiaolan Shi, Haitao Front Med (Lausanne) Medicine OBJECTIVE: To analyze the prevalence, associated comorbidities, influencing factors, and identifying factors of non-obese fatty liver disease and to provide a reference for its prevention and treatment. MATERIALS AND METHODS: Firstly, to screen data obtained from the physical examinations of individuals conducted in the Second Affiliated Hospital of Xi’an Jiaotong University in 2021, subjects with complete data of abdominal ultrasonography, body mass index, age and sex were selected to analyze the prevalence of fatty liver disease and non-obese fatty liver disease. Secondly, to screen non-obese subjects who had data for triglycerides, fasting blood glucose, and so on, to analyze the complications, influencing factors, and identifying factors of non-obese fatty liver disease. RESULTS: The prevalence of fatty liver disease was 27.8% (18,416/66,221), including 33.9% (11,921/35,131) in males and 20.9% (6,495/31,090) in females, revealing that the prevalence was significantly higher in males than in females (P < 0.001). There were 40,673 non-obese subjects screened in total, and the prevalence of non-obese fatty liver disease was 13.0% (5,307/40,673). The prevalence of non-obese fatty liver disease was 13.3% (2,208/16,572) in males and 12.9% (3,099/24,101) in females; the difference was not statistically significant (P = 0.17). The serum triglycerides level was elevated in 54.2% of subjects with non-obese fatty liver disease, and this was the most common abnormal metabolic index accompanying the disease. Logistic regression analysis showed that gender, age, body mass index, blood pressure, alanine aminotransferase, aspartate aminotransferase, fasting blood glucose, triglycerides, total cholesterol, and serum uric acid were independent risk factors for non-obese fatty liver disease (P < 0.001). For triglycerides, the area under the receiver operating characteristic curve in predicting non-obese fatty liver disease was the greatest (0.806). CONCLUSION: The prevalence of fatty liver disease and non-obese fatty liver disease determined by the physical examination of individuals was high, and the triglycerides is likely to be useful for the extensive screening of non-obese fatty liver disease. Frontiers Media S.A. 2022-11-15 /pmc/articles/PMC9705575/ /pubmed/36457563 http://dx.doi.org/10.3389/fmed.2022.1038475 Text en Copyright © 2022 Gao, Deng, Wang, Zhou, Yao, Zhou, Xing, Wang, Lu and Shi. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Gao, Ning Deng, Jiang Wang, Jinhai Zhou, Zhihua Yao, Cong Zhou, Mimi Xing, Xin Wang, Qian Lu, Xiaolan Shi, Haitao The prevalence, comorbidities, influencing factors, and identifying factors of non-obese fatty liver disease |
title | The prevalence, comorbidities, influencing factors, and identifying factors of non-obese fatty liver disease |
title_full | The prevalence, comorbidities, influencing factors, and identifying factors of non-obese fatty liver disease |
title_fullStr | The prevalence, comorbidities, influencing factors, and identifying factors of non-obese fatty liver disease |
title_full_unstemmed | The prevalence, comorbidities, influencing factors, and identifying factors of non-obese fatty liver disease |
title_short | The prevalence, comorbidities, influencing factors, and identifying factors of non-obese fatty liver disease |
title_sort | prevalence, comorbidities, influencing factors, and identifying factors of non-obese fatty liver disease |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705575/ https://www.ncbi.nlm.nih.gov/pubmed/36457563 http://dx.doi.org/10.3389/fmed.2022.1038475 |
work_keys_str_mv | AT gaoning theprevalencecomorbiditiesinfluencingfactorsandidentifyingfactorsofnonobesefattyliverdisease AT dengjiang theprevalencecomorbiditiesinfluencingfactorsandidentifyingfactorsofnonobesefattyliverdisease AT wangjinhai theprevalencecomorbiditiesinfluencingfactorsandidentifyingfactorsofnonobesefattyliverdisease AT zhouzhihua theprevalencecomorbiditiesinfluencingfactorsandidentifyingfactorsofnonobesefattyliverdisease AT yaocong theprevalencecomorbiditiesinfluencingfactorsandidentifyingfactorsofnonobesefattyliverdisease AT zhoumimi theprevalencecomorbiditiesinfluencingfactorsandidentifyingfactorsofnonobesefattyliverdisease AT xingxin theprevalencecomorbiditiesinfluencingfactorsandidentifyingfactorsofnonobesefattyliverdisease AT wangqian theprevalencecomorbiditiesinfluencingfactorsandidentifyingfactorsofnonobesefattyliverdisease AT luxiaolan theprevalencecomorbiditiesinfluencingfactorsandidentifyingfactorsofnonobesefattyliverdisease AT shihaitao theprevalencecomorbiditiesinfluencingfactorsandidentifyingfactorsofnonobesefattyliverdisease AT gaoning prevalencecomorbiditiesinfluencingfactorsandidentifyingfactorsofnonobesefattyliverdisease AT dengjiang prevalencecomorbiditiesinfluencingfactorsandidentifyingfactorsofnonobesefattyliverdisease AT wangjinhai prevalencecomorbiditiesinfluencingfactorsandidentifyingfactorsofnonobesefattyliverdisease AT zhouzhihua prevalencecomorbiditiesinfluencingfactorsandidentifyingfactorsofnonobesefattyliverdisease AT yaocong prevalencecomorbiditiesinfluencingfactorsandidentifyingfactorsofnonobesefattyliverdisease AT zhoumimi prevalencecomorbiditiesinfluencingfactorsandidentifyingfactorsofnonobesefattyliverdisease AT xingxin prevalencecomorbiditiesinfluencingfactorsandidentifyingfactorsofnonobesefattyliverdisease AT wangqian prevalencecomorbiditiesinfluencingfactorsandidentifyingfactorsofnonobesefattyliverdisease AT luxiaolan prevalencecomorbiditiesinfluencingfactorsandidentifyingfactorsofnonobesefattyliverdisease AT shihaitao prevalencecomorbiditiesinfluencingfactorsandidentifyingfactorsofnonobesefattyliverdisease |